{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T18:33:43Z","timestamp":1649183623248},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1157\/13109835","type":"journal-article","created":{"date-parts":[[2007,10,8]],"date-time":"2007-10-08T16:45:49Z","timestamp":1191861949000},"page":"448-450","source":"Crossref","is-referenced-by-count":0,"title":["Terapia biol\u00f3gica con anticuerpos anti factor de necrosis tumoral, \u00bfampliando el espectro de sus indicaciones?"],"prefix":"10.1016","volume":"207","author":[{"given":"M.","family":"L\u00f3pez Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Garc\u00eda Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"G\u00f3mez Cerezo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13109835_bib1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2004.08.004","article-title":"Potential offlabel use of infliximab in autoimmune and non-autoimmune diseases: a review","volume":"4","author":"Atzeni","year":"2005","journal-title":"Autoimm Rev"},{"key":"10.1157\/13109835_bib2","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1111\/j.1572-0241.2002.07029.x","article-title":"Cytokine profile in colonic mucosa in ulcerative colitis correlates with disease activity and response to granulocytapheresis","volume":"97","author":"Tsukada","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1157\/13109835_bib3","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/01.mcg.0000140188.88275.65","article-title":"Current therapeutic recommendations: infliximab for ulcerative colitis","volume":"38","author":"Shen","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1157\/13109835_bib4","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Eng J Med"},{"key":"10.1157\/13109835_bib5","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1378\/chest.127.3.1064","article-title":"Treatment of sarcoidosis with infliximab","volume":"127","author":"Doty","year":"2005","journal-title":"Chest"},{"key":"10.1157\/13109835_bib6","first-page":"A495","article-title":"Double-blind, randomized trial of a tumor necrosis factor receptor antagonist (etanercept) for treatment of chronic ocular sarcoidosis","volume":"165","author":"Baughman","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1157\/13109835_bib7","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.V75.4.1024.1024","article-title":"Treatment of moderate\/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome","volume":"75","author":"Weisdorf","year":"1990","journal-title":"Blood"},{"key":"10.1157\/13109835_bib8","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2003-12-4241","article-title":"Tumor necrosis factor-alpha blockade for the treatment of acute GVHD","volume":"104","author":"Couriel","year":"2004","journal-title":"Blood"},{"key":"10.1157\/13109835_bib9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/ard.2004.024026","article-title":"Tumor necrosis factor alpha blocking agents in refractory adult Still\u2019s disease: an observational study of 20 cases","volume":"64","author":"Fautrel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1157\/13109835_bib10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener\u2019s ganulomatosis","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1157\/13109835_bib11","first-page":"666","article-title":"Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener\u2019s granulomatosis","volume":"24","author":"Nassonov","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1157\/13109835_bib12","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/art.22327","article-title":"Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus","volume":"56","author":"Aringer","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1157\/13109835_bib13","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1157\/13109835_bib14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","article-title":"Current concepts in the etiology and treatment of Beh\u00e7et disease","volume":"50","author":"Evereklioglu","year":"2005","journal-title":"Surv ophthalmol"},{"key":"10.1157\/13109835_bib15","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","article-title":"Infliximab for recurrent sight-threatening ocular inflammation in adamantiades-Beh\u00e7et disease","volume":"140","author":"Sfikakis","year":"2004","journal-title":"Ann Intern Med"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014256507734392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014256507734392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T02:43:29Z","timestamp":1587955409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014256507734392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0014256507734392"],"URL":"https:\/\/doi.org\/10.1157\/13109835","relation":{},"ISSN":["0014-2565"],"issn-type":[{"value":"0014-2565","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}